Nevro Corp Stock News

Wednesday, March 1, 2023 at 8:45 am Eastern Time REDWOOD CITY, Calif. , Feb. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-c

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.

Within the last quarter, Nevro (NYSE:NVRO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 7 2 0 Last 30D 0 0 0 1

Company to Host Conference Call on Thursday, February 16, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , Jan. 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device compan

Upgrades For Casa Systems Inc (NASDAQ:CASA), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform. Casa Systems earned $0.29 in the third quarter, compared to $0.05 i

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics earned $0.44 in the third quarter, compared to $0.78 in th

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.

Upgrades Canaccord Genuity upgraded the previous rating for Nevro Corp (NYSE:NVRO) from Hold to Buy. In the third quarter, Nevro showed an EPS of $0.59, compared to $0.87 from the year-ago quarter. Th

Upgrades For Colliers International Group Inc (NASDAQ:CIGI), Goldman Sachs upgraded the previous rating of Neutral to Buy. Colliers Intl Gr earned $1.41 in the third quarter, compared to $1.27 in the

Analysts have provided the following ratings for Nevro (NYSE:NVRO) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 1 0 Last 30D 0

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Obtained FDA approval for its Senza HFX iQ spinal cord stimulation system in October. Revenue growth was reported at 8% YoY and lifted to $100.5mm on adjusted EBITDA of negative $3.8mm.